<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We developed and tested a potent hexameric Fas <z:chebi fb="4" ids="48705">agonist</z:chebi>, termed MegaFasL, for its cytotoxic effects on a panel of human haematopoietic malignant cells and healthy human haematopoietic progenitor cells (CD34+CD38low) </plain></SENT>
<SENT sid="1" pm="."><plain>Results demonstrated that MegaFasL induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in cell lines and primary cells representing <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (MM), <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (ALL) and Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Cells from a <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:mp ids='MP_0005481'>CML</z:mp>) line and from patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> lymphocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (CLL) were resistant </plain></SENT>
<SENT sid="3" pm="."><plain>Furthermore, CD34+CD38low progenitor cells were also resistant to MegaFasL </plain></SENT>
<SENT sid="4" pm="."><plain>The data indicate that MegaFasL could be a highly efficient therapeutic agent ex vivo or potentially in vivo </plain></SENT>
</text></document>